1. Understanding Comparative Effectiveness Data in Psoriatic Arthritis

3. Evolving Complexity of the Biologic Treatment Landscape for PsA

4. Treatment Schema for Active PsA: GRAPPA

5. Comparison of EULAR and GRAPPA Recommendations

6. Secukinumab in PsA: FUTURE 5 Clinical Trial

7. Tofacitinib in PsA: OPAL Clinical Trials

8. How Can Clinicians Make Treatment Decisions?

9. Real-World Evidence

10. Randomized Control Trials vs Real-World Evidence

11. How Can Clinicians Make Treatment Decisions? (cont)

12. MAIC: The Why and the How

13. Anchored and Unanchored Analyses

14. Comparison of Methods: Summary of Pros and Cons

15. NICE Recommendations for Comparative Effectiveness

16. Key Takeaways From NMA Studies

17. Key Takeaways From NMA Studies (cont)

18. MAIC: Methodology

19. MAIC: Methodology (cont)

20. ADA vs ETA vs INF

21. ADA vs SEC: ADEPT vs Pooled FUTURE 1 and 2

22. ADA vs SEC: ADEPT vs Pooled FUTURE 1 and 2 (cont)

23. SEC vs ADA: Pooled FUTURE 1 and 2 vs ADEPT

24. SEC vs ADA: Pooled FUTURE 1 and 2 vs ADEPT (cont)

25. SEC vs ADA: FUTURE 2 vs ADEPT

26. SEC vs ADA: FUTURE 2 vs ADEPT (cont)

27. SEC vs INF: Pooled FUTURE 1 and 2 vs IMPACT 2

28. SEC vs INF: Pooled FUTURE 1 and 2 vs IMPACT 2 (cont)

29. Clinical Insights Based on the Totality of Evidence

30. Therapeutic Landscape for PsA Is Expanding

31. Ongoing Head-To-Head Studies

32. Conclusions

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)